• Knowledge Base
  • |
  • Construction Market Trends
  • |
  • Science and Tech Market Trends

What Drug Process Manufacturing Construction Really Demands

July 21, 2026

KEY TAKEAWAYS 

  • Process manufacturing construction requires complex planning to ensure safety and compliance and get plants operating sooner.
  • Early construction management with smart estimating is a big factor in protecting schedules and project budgets.
  • The right construction partner brings process pharma experience and understands how their work supports FDA requirements.

If you’ve been watching the pharmaceutical industry lately, then you’ve seen the headlines. Billions of dollars are pouring into new drug manufacturing facilities across the country. This is largely driven by the GLP-1 boom, domestic supply chain mandates, and a wave of new drug entrants racing to scale.[1] That demand is real, and so is the complexity of building the facilities to meet it.

Process manufacturing construction comes with its own set of challenges: long permit timelines, intricate mechanical, engineering, and plumbing (MEP) coordination, specialized safety and compliance requirements, and a post-construction qualification process that can stretch for months before a facility generates revenue. Getting any one of those wrong can set a project back significantly.

Riley Construction has been working in pharmaceutical and life sciences construction for decades. We’ve seen what happens when construction complexity catches project owners off guard. We know how to help them get ahead of it.

Plan ahead to address complex designs

Process manufacturing facilities are complex to build precisely because of what goes inside them. Extensive process piping, large-scale reactors and vessels, explosion-proof design requirements, hazardous material zoning, specialized ventilation and fire suppression. All of these components must be sequenced, coordinated, and executed in the right order, and often inside or adjacent to an operating facility.

That translates to a level of MEP coordination and trade sequencing that is in a different category than standard commercial or even lab construction. Production shutdowns must be planned well in advance using a phased approach that ensures teams can safely meet deadlines and stay on schedule. The margin for error is slim, not just for schedule and budget reasons, but because the qualification and validation work that follows construction depends on what we build and how we build it.

“Every delay you create upfront by skipping proper planning, the right conversations, and solid scheduling costs you later because your FDA approval clock doesn’t start until construction is done.” – Joe Gilbert, Owner and Project Executive, Riley Construction

Don’t Underestimate the Timeline

Many companies entering the process manufacturing space want to plan their construction with timelines aligned with their clinical development schedules or investor commitments, not with construction and regulatory realities.

Getting a drug manufacturing facility from concept to operational isn’t a 12-month project. Between permitting, design development, equipment procurement (with lead times that can stretch 12 to 52 weeks or more), construction, commissioning, and the FDA qualification and validation process that follows, you can sometimes be looking at multiple years before the first trial batch runs. And that’s before the regulatory review cycle that must occur before any product generates revenue.

The result is a compressed window that puts every phase of the project under pressure. When decisions are rushed and budgets are set before anyone has real cost data, the consequences show up in the field, where they’re most expensive to fix.

Start Construction Management Early

The biggest factor a manufacturer can control to protect schedule and budget isn’t choosing the best contractor bid. It’s earlier construction management involvement.

Riley has seen both sides of this. On one project, construction management started the project after design and schedule were already locked. The project struggled with budget pressures and slipping timelines. On another, Riley was engaged early, contributing constructability reviews and real market-rate cost data before commitments were made. That project was funded appropriately and executed more smoothly, despite similar complexity.

Early involvement enables:

  • Constructability reviews that catch design conflicts before they hit the field
  • Schedule development that accounts for permitting, lead times, and shutdowns
  • Real-time cost estimating using current market rates, not outdated benchmarks
  • Risk identification before decisions are locked in

Understand Who Owns Safety and Compliance

The pharmaceutical company’s quality team owns the validation master plan and GMP documentation. However, construction teams still have to build to those standards. This means added code requirements: explosion-proof design, blast panels, and hot work coordination around hazardous materials that don’t come up in typical commercial or lab construction.

The FDA’s 2025 PreCheck Pilot Program is helping here. They offer early technical engagement for qualifying domestic facilities and favoring modular and prefabricated construction methods. It’s a more supportive environment than in years past, but only for construction teams who understand how their work ties into the validation process ahead.

What to Look for in a Construction Partner for Process Pharma

This drug development center, built by Riley Construction for a global pharmaceutical manufacturer, supports preclinical and clinical development of new and existing compounds. The facility includes four potent drug process suites and three non-potent drug process suites.

Not all construction firms with clean room experience have built process pharmaceutical manufacturing facilities. When evaluating a partner, ask:

  • Have they handled explosion-proof design and hazardous material zoning?
  • Can they sequence complex MEP and process piping in operating facilities?
  • Do they bring current market-rate cost data, not outdated benchmarks, to pre-design?
  • Have they worked through FDA commissioning, qualification, and validation?
  • Will they engage early enough to shape schedule and budget before drawings are done?

The right partner understands the full project arc, including the long runway before a facility generates revenue, and prices and sequences the work accordingly.

Riley Construction has built these facilities. We know where the risk lives and how to manage it. To learn more about Riley Construction’s science and technology experience, reach out to Joe Gilbert, Owner and Project Executive at joeg@rileycon.com.

[1] https://intuitionlabs.ai/articles/glp-1-drug-manufacturing-cdmo-tech-transfer

Categories: